Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 156, Issue 1, 2011, Pages 67-71

  Yasmin, Ephia ^a   Glanville, Julie ^a   Barth, Julian ^a   Balen, Adam H ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Body mass index; Insulin resistance; Metformin; Polycystic ovary syndrome

Indexed keywords

FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; METFORMIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ACANTHOSIS NIGRICANS; ACNE; ADULT; AMENORRHEA; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HIRSUTISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETHARGY; MENSTRUAL CYCLE; NAUSEA; OLIGOMENORRHEA; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 79955596156     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2010.12.041     Document Type: Article

References (22)

1. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980;50:113-6. (Pubitemid 10203585)
2. Balen AH. Pathogenesis of polycystic ovary syndrome - the enigma unravels? Lancet 1999;354-966.
3. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000;15:1266-74. (Pubitemid 30335948)
4. Dunaif A. Insulin resistance in polycystic ovarian syndrome. Ann N Y Acad Sci 1993;28(687):60-4. (Pubitemid 23217925)
5. Legro RS, Castracane VD, Kauffmann RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynaecol Surv 2004;59: 141-54. (Pubitemid 38140845)
6. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fert Stert 2002;77:1095-105. (Pubitemid 34626313)
7. Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. The biological variation of insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:1560-2. (Pubitemid 34615239)
8. Velasquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinaemia, insulin resistance, hyperandrogenaemia and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54. (Pubitemid 24145474)
9. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action and ovarian setroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:24-530.
10. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews 2010;(1). Art. No.: CD003053. doi:10.1002/14651858. CD003053.pub4.
11. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269-74. (Pubitemid 28154775)
12. Nestler JE. Should patients with polycystic ovarian syndrome be treated with metformin? An enthusiastic endorsement. Hum Reprod 2002;17:1950-3.
13. Eisenhardt S, Schwarzmann N, Henschel V, Germeyer A, von Wolff M, Hamann A, Strowitzki T. Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2006;91:946-52. (Pubitemid 43357763)
14. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
15. Quon MJ, Cochran C, Taylor SI, Eastman RC. Direct comparison of standard and insulin modified protocols for minimal model estimation of insulin sensitivity in normal subjects. Diabetes Res 1994;25:139-49.
16. Cawood ML, Field HP, Ford CG, Gillingwater S, Kicman A, Cowan D, Barth JH. Testosterone measurement by isotope-dilution liquid chromatography-tandem mass spectrometry; validation of a method for routine clinical practise. Clin Chem 2005;51:1472-9.
17. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-46. (Pubitemid 32268804)
18. Fleming R, Hopkinson ZE, Wallace AM, Greer IA, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569-74. (Pubitemid 34158220)
19. Haas DA, Carr BR, Attia GR. effects of metformin on body mass index, menstrual cyclicity and ovulation induction in women with polycystic ovary syndrome. Fertil Steril 2003;79:469-81. (Pubitemid 36293436)
20. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005;90:4593-8. (Pubitemid 41159348)
21. Bruno RV, de Avilla MA, Neves FB, Nardi Ae, Crespo CM, Sobrinho AT. Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference. Fertil Steril 2007;88:510-2. (Pubitemid 47212150)
22. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone binding globulin in polycystic ovary syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003;88:1528-33. (Pubitemid 36623365)